Nikos Pantazis1, Kholoud Porter2, Dominique Costagliola3, Andrea De Luca4, Jade Ghosn5, Marguerite Guiguet6, Anne M Johnson7, Anthony D Kelleher8, Charles Morrison9, Rodolphe Thiebaut10, Linda Wittkop10, Giota Touloumi11. 1. Athens University Medical School, Athens, Greece. Electronic address: npantaz@med.uoa.gr. 2. MRC Clinical Trials Unit at UCL, London, UK. 3. INSERM, U1136, Paris, France; UPMC Université Paris 06, UMR S1136, Paris, France; AP-HP, Groupe hospitalier Pitié-Salpétrière, Service des maladies infectieuses et tropicales, Paris, France. 4. Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy; Unit of Infectious Diseases, Siena University Hospital, Siena, Italy. 5. AP-HP, Hôpital Bicêtre, Service de médecine interne, Le Kremlin-Bicêtre, Paris, France; Faculté de Médecine site Necker, Université Paris Descartes, EA 3620, Paris, France. 6. INSERM, U1136, Paris, France; UPMC Université Paris 06, UMR S1136, Paris, France. 7. Research Department of Infection and Population Health, University College London, London, UK. 8. Kirby Institute, UNSW, Sydney, NSW, Australia. 9. FHI 360, Durham, NC, USA. 10. INSERM U897 Centre of Epidemiology and Biostatistics, ISPED Bordeaux School of Public Health, University Bordeaux Segalen, Bordeaux, France. 11. Athens University Medical School, Athens, Greece.
Abstract
BACKGROUND: Measures of CD4 T-cell count and HIV-1 plasma viral load before antiretroviral therapy are proxies for virulence. Whether these proxies are changing over time has implications for prevention and treatment. The aim of this study was to investigate those trends. METHODS: Data were derived from the Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE) collaboration of mainly European seroconverter cohorts. Longitudinal CD4 cell counts and plasma viral load measurements before the initiation of antiretroviral therapy or AIDS onset were analysed by use of linear or fractional polynomials mixed models adjusting for all available potential confounders. Calendar time effects were modelled through natural cubic splines. FINDINGS: 15 875 individuals seroconverting from 1979 to 2008 fulfilled the inclusion criteria; 3215 (20·3%) were women; median follow-up was 31 months (IQR 14-62); dropout before starting antiretroviral therapy or AIDS onset was 8·1%. Estimated CD4 counts at seroconversion for a typical individual declined from about 770 cells per μL (95% CI 750-800) in the early 1980s to a plateau of about 570 cells per μL (555-585) after 2002. CD4 cell rate of loss increased up to 2002. Estimated set-point plasma viral loads increased from 4·05 log10 copies per mL (95% CI 3·98-4·12) in 1980 to 4·50 log10 copies per mL (4·45-4·54) in 2002 with a tendency of returning to lower loads thereafter. Results were similar when we restricted analyses to various subsets, including adjusting for plasma viral load assay, censored follow-up at 3 years, or used variations of the main statistical approach. INTERPRETATION: Our results provide strong indications of increased HIV-1 virulence and transmissibility during the course of the epidemic and a potential plateau effect after about 2002. FUNDING: European Union Seventh Framework Programme.
BACKGROUND: Measures of CD4 T-cell count and HIV-1 plasma viral load before antiretroviral therapy are proxies for virulence. Whether these proxies are changing over time has implications for prevention and treatment. The aim of this study was to investigate those trends. METHODS: Data were derived from the Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE) collaboration of mainly European seroconverter cohorts. Longitudinal CD4 cell counts and plasma viral load measurements before the initiation of antiretroviral therapy or AIDS onset were analysed by use of linear or fractional polynomials mixed models adjusting for all available potential confounders. Calendar time effects were modelled through natural cubic splines. FINDINGS: 15 875 individuals seroconverting from 1979 to 2008 fulfilled the inclusion criteria; 3215 (20·3%) were women; median follow-up was 31 months (IQR 14-62); dropout before starting antiretroviral therapy or AIDS onset was 8·1%. Estimated CD4 counts at seroconversion for a typical individual declined from about 770 cells per μL (95% CI 750-800) in the early 1980s to a plateau of about 570 cells per μL (555-585) after 2002. CD4 cell rate of loss increased up to 2002. Estimated set-point plasma viral loads increased from 4·05 log10 copies per mL (95% CI 3·98-4·12) in 1980 to 4·50 log10 copies per mL (4·45-4·54) in 2002 with a tendency of returning to lower loads thereafter. Results were similar when we restricted analyses to various subsets, including adjusting for plasma viral load assay, censored follow-up at 3 years, or used variations of the main statistical approach. INTERPRETATION: Our results provide strong indications of increased HIV-1 virulence and transmissibility during the course of the epidemic and a potential plateau effect after about 2002. FUNDING: European Union Seventh Framework Programme.
Authors: Santiago Avila-Rios; Jonathan M Carlson; Mina John; Simon Mallal; Zabrina L Brumme Journal: Curr Opin HIV AIDS Date: 2019-05 Impact factor: 4.283
Authors: Lele Zhao; Chris Wymant; François Blanquart; Tanya Golubchik; Astrid Gall; Margreet Bakker; Daniela Bezemer; Matthew Hall; Swee Hoe Ong; Jan Albert; Norbert Bannert; Jacques Fellay; M Kate Grabowski; Barbara Gunsenheimer-Bartmeyer; Huldrych F Günthard; Pia Kivelä; Roger D Kouyos; Oliver Laeyendecker; Laurence Meyer; Kholoud Porter; Ard van Sighem; Marc van der Valk; Ben Berkhout; Paul Kellam; Marion Cornelissen; Peter Reiss; Christophe Fraser; Luca Ferretti Journal: Virus Evol Date: 2022-03-16
Authors: Nicholas D Mullins; Nuala M Maguire; Alan Ford; Kalyan Das; Eddy Arnold; Jan Balzarini; Anita R Maguire Journal: Org Biomol Chem Date: 2016-02-28 Impact factor: 3.876
Authors: François Blanquart; Mary Kate Grabowski; Joshua Herbeck; Fred Nalugoda; David Serwadda; Michael A Eller; Merlin L Robb; Ronald Gray; Godfrey Kigozi; Oliver Laeyendecker; Katrina A Lythgoe; Gertrude Nakigozi; Thomas C Quinn; Steven J Reynolds; Maria J Wawer; Christophe Fraser Journal: Elife Date: 2016-11-05 Impact factor: 8.140
Authors: Jacques D A Ndawinz; Xavier Anglaret; Eric Delaporte; Sinata Koulla-Shiro; Delphine Gabillard; Albert Minga; Dominique Costagliola; Virginie Supervie Journal: Bull World Health Organ Date: 2015-06-01 Impact factor: 9.408
Authors: Leigh F Johnson; Margaret T May; Rob E Dorrington; Morna Cornell; Andrew Boulle; Matthias Egger; Mary-Ann Davies Journal: PLoS Med Date: 2017-12-12 Impact factor: 11.069